RxDoctor Payments Data

Jennifer West, APRN

Family · Whitley City, KYNPI 1184852659

Payments from drug & device makers

$1,597in general payments, 2019–2025

Across 95 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$387
  • GSK$335
  • AbbVie$178
  • Novo Nordisk$135
  • Lilly USA, LLC$129
  • AstraZeneca$101
  • plus $333 from 15 others

What the payments were for

  • Food & beverage$1,597100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,597 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$3,197
Medicare patients
66
Services billed
125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide87$102,476
EliquisApixaban63$52,483
LinzessLinaclotide53$32,501
JardianceEmpagliflozin28$29,196
TrulicityDulaglutide25$25,980
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$24,207
JanuviaSitagliptin Phosphate23$22,725
VascepaIcosapent Ethyl28$20,313
FarxigaDapagliflozin Propanediol22$19,725
TradjentaLinagliptin21$15,846
MounjaroTirzepatide13$15,723
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$14,743
Tresiba Flextouch U-200Insulin Degludec12$7,120
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$5,544
Breo ElliptaFluticasone/Vilanterol11$4,405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$135$102,47687 claims
PfizerEliquis, Dilantin, Dilantin$12$56,25989 claims
Boehringer IngelheimJardiance, Tradjenta$41$45,04249 claims
Lilly USA, LLCTrulicity, Mounjaro$129$41,70438 claims
AstraZenecaFarxiga, Breztri Aerosphere$101$34,46838 claims
AbbVieLinzess$178$32,50153 claims
GSKTrelegy Ellipta, Breo Ellipta$335$28,61136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.

Other family in Whitley City

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →